Slide 1: GSK Oncology R&D Update
GSK Oncology R&D Update Axel Hoos, MD Senior Vice President, Oncology R&D February 2019
Slide 2: Cautionary statement regarding forward-looking statements
Cautionary statement regarding forward-looking statements This presentation may contain forward-looking statements. Forward-looking statements give the Group’s current expectations or forecasts of future events. An investor can identify these statements by the fact that they do not relate strictly t
Slide 3: Increased oncology focus via BD and governance
Innovation Increased oncology focus via BD and governance 16* assets in clinical development; potential for 3 launches in 2020 Phase II Phase I Phase III Mechanism (dose (FTIH) (pivotal) expansion) † PARP inhibitor (Zejula, niraparib) First line maintenance ovarian, other solid tumours under investi
Slide 4: New alliance with Merck is an opportunity to further accelerate our oncology strategy
Innovation New alliance with Merck* is an opportunity to further accelerate our oncology strategy Current clinical status Complements existing assets Immuno-modulatory biological Encouraging NSCLC data presented mechanism fits with our new R&D approach Phase II underway versus pembrolizumab as 1L in
Slide 5: PARP inhibitors: wider application than has been appreciated
Innovation PARP inhibitors: wider application than has been appreciated High grade serous ovarian cancer* – PARP inhibitors have transformed the treatment of ovarian cancer gBRCA (15%) – Prior to the publication of TESARO’s NOVA study, PARP inhibitors were thought to only non-gBRCA HRD- benefit pati
Slide 6: GSK'916 (BCMA ADC): aggressive development plan in multiple myeloma advancing rapidly
Innovation GSK‘916 (BCMA ADC): aggressive development plan in multiple myeloma advancing rapidly July 2018 February 2019 – Initiated DREAMM-2 4L monotherapy – DREAMM-2 enrolled faster than expected pivotal study – Planned 130 patients enrolled by Oct 2018 –1st subject dosed early July – High study s
Slide 7: do more, feel better, live longer
do more feel better live longer Q&A